相关实验视频

Updated: Jan 15, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

打破乳腺癌的障碍:多目标治疗见解

Apsara Unni¹, Kalirajan Rajagopal¹, Krishna Shevate¹

¹Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, 643001, The Nilgiris, Tamil Nadu, India.

Mini reviews in medicinal chemistry

|October 15, 2025

概括

多重向疗法显示出克服乳腺癌治疗失败的希望. 识别KAT6A等生物标志物和结合新型抑制剂可以改善晚期或耐火性疾病患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

乳腺癌是女性癌症死亡的主要原因,其特点是分子异质性和可变的治疗反应.
治疗耐药性和复发仍然是重大的临床挑战,尽管在激素治疗,向药物和免疫治疗方面取得了进展.

研究的目的:

审查乳腺癌多向治疗的创新.
阐明与新型治疗剂相关的治疗失败背后的生物学机制.
确定新的分子标和组合策略,以改善乳腺癌治疗.

主要方法:

对针对乳腺癌的多向治疗方法的当前文献的综述.
检查关键的分子通路,包括ER,HER2,EGFR,VEGFR,PI3K/AKT/mTOR,MAPK,PARP和CDK4/6.6等.
确定KAT6A作为潜在的生物标志物和治疗点,并对新型临床药物和组合策略进行分析.

主要成果:

在ER+乳腺癌中放大素乙酶KAT6A显示出作为CDK4/6抑制剂有效性的生物标志物和表观遗传治疗标的潜力.
选择性KAT6抑制剂的开发,可能被Menin抑制剂增强,可以克服内分泌抵抗.
分析CDK4/6突变,抗药机制,以及抗体与药物合物的有效性,如trastuzumab deruxtecan.

结论:

多途径向策略为解决乳腺癌当前单一疗法的局限性提供了一个有希望的方法.
KAT6A生物标志物实用性和新型抑制剂可以为治疗决策提供信息,并改善耐药乳腺癌的结果.
未来的乳腺癌治疗需要由分子分析和耐药性生物标志物指导的组合策略,以实现个性化治疗方法.

关键词:

乳腺癌乳腺癌乳腺癌在KAT6A.生物标志物生物标志物激素受体激素受体激素受体具有多个目标的多重目标.铁氨酸激酶酶的使用方法

更多相关视频

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...